6,7-二甲氧基异喹啉-3-羧酸 | 120373-06-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 中文名称: 6,7-二甲氧基异喹啉-3-羧酸
• 英文名称: 6,7-dimethoxyisoquinoline-3-carboxylic acid
• 英文别名: 6,7-dimethoxy-3-isoquinolinecarboxylic acid
• CAS: 120373-06-0
• 化学式: C₁₂H₁₁NO₄
• 分子量: 233.224
• InChiKey: MIPKQHRPGRGBIU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  68.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  6,7-二甲氧基异喹啉-3-羧酸 生成 6,7-Dimethoxy-N-(2-oxo-1-imidazolidinyl)-3-isoquinolinecarboxamide
  参考文献：
  名称：

  SLUSARCHYK, WILLIAM A.;ERMANN, PETER H.

  摘要：

  DOI：
• 作为产物：
  描述：

  methyl (S)‐6,7‐dimethoxy‐1,2,3,4‐tetrahydroisoquinoline‐3‐carboxylate 在 palladium 10% on activated carbon 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 5,5-dimethyl-1,3-cyclohexadiene 、 水 为溶剂， 反应 72.0h， 生成 6,7-二甲氧基异喹啉-3-羧酸
  参考文献：
  名称：

  Design, syntheses, and pharmacological characterization of 17-cyclopropylmethyl-3,14β-dihydroxy-4,5α-epoxy-6α-(isoquinoline-3′-carboxamido)morphinan analogues as opioid receptor ligands

  摘要：

  A series of 17-cyclopropylmethyl-3,14 beta-dihydroxy-4,5 alpha-epoxy-6 alpha-(isoquinoline-3 '-carboxamido)morphinan (NAQ) analogues were synthesized and pharmacologically characterized to study their structure-activity relationship at the mu opioid receptor (MOR). The competition binding assay showed two-atom spacer and aromatic side chain were optimal for MOR selectivity. Meanwhile, substitutions at the 1 '- and/or 4 '-position of the isoquinoline ring retained or improved MOR selectivity over the kappa opioid receptor while still possessing above 20-fold MOR selectivity over the delta opioid receptor. In contrast, substitutions at the 6 '- and/or 7 '-position of the isoquinoline ring reduced MOR selectivity as well as MOR efficacy. Among this series of ligands, compound 11 acted as an antagonist when challenged with morphine in warm-water tail immersion assay and produced less significant withdrawal symptoms compared to naltrexone in morphine-pelleted mice. Compound 11 also antagonized the intracellular Ca2+ increase induced by DAMGO. Molecular dynamics simulation studies of 11 in three opioid receptors indicated orientation of the 6 '-nitro group varied significantly in the different 'address' domains of the receptors and played a crucial role in the observed binding affinities and selectivity. Collectively, the current findings provide valuable insights for future development of NAQ-based MOR selective ligands. Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmc.2015.02.055

文献信息

• [EN] COMPOSITIONS FOR THE TREATMENT OF BRAIN TUMORS<br/>[FR] COMPOSITIONS DESTINÉES AU TRAITEMENT DE TUMEURS CÉRÉBRALES
  申请人：INNOCRIN PHARMACEUTICALS INC

  公开号：WO2019182743A1

  公开（公告）日：2019-09-26

  The instant invention describes pharmaceutical compositions and dosing regimens comprising seviteronel and/or dexamethasone, and methods of treating diseases, disorders symptoms thereof.

  这项即时发明描述了包含赛维特龙和/或地塞米松的药物组合物和给药方案，以及治疗疾病、疾病症状的方法。
• [EN] COMPOSITIONS FOR THE TREATMENT OF BRAIN TUMORS<br/>[FR] COMPOSITIONS POUR LE TRAITEMENT DE TUMEURS CÉRÉBRALES
  申请人：INNOCRIN PHARMACEUTICALS INC

  公开号：WO2020077197A1

  公开（公告）日：2020-04-16

  The instant invention describes pharmaceutical compositions and dosing regimens comprising radiation therapy and seviteronel with or without dexamethasone, and methods of treating diseases, disorders or symptoms thereof.

  这项即时发明描述了包括放射治疗和赛维特鲁内尔在内或不包括地塞米松的药物组合物和给药方案，以及治疗疾病、疾病或症状的方法。
• Nitrogen-containing heterocycle derivatives, pharmaceutical compositions, and methods of use thereof as antiviral agents
  申请人：Mjalli M.M. Adnan

  公开号：US20070219239A1

  公开（公告）日：2007-09-20

  The present application provides nitrogen-containing heterocycle derivatives that are antiviral compounds that may be useful in the treatment of a viral infection. Compounds of Formula (I) and pharmaceutical compositions comprising a compound of Formula (I) may be administered to a subject for antiviral therapy or prophylaxis.

  本申请提供了含氮杂环衍生物，这些衍生物是抗病毒化合物，可能在治疗病毒感染方面有用。具有式（I）的化合物和包含式（I）化合物的药物组合物可用于向受试者施行抗病毒治疗或预防。
• 2-oxo-1-[[(substituted sulfonyl)amino]-carbonyl]azetidines
  申请人：E. R. Squibb & Sons, Inc.

  公开号：US04777252A1

  公开（公告）日：1988-10-11

  Antibacterial activity is exhibited by 3-acylamino-2-oxoazetidines having in the 1-position an activating group of the formula ##STR1## wherein R is ##STR2## and R.sub.4 is ##STR3##

  3-酰氨基-2-氧代杂环丁烷具有抗菌活性，在1-位置带有如下式中的活化基团##STR1##其中R为##STR2##，R.sub.4为##STR3##
• METALLOENZYME INHIBITOR COMPOUNDS
  申请人：Innocrin Pharmaceuticals, Inc.

  公开号：US20170143694A1

  公开（公告）日：2017-05-25

  The instant invention describes compounds having metalloenzyme modulating activity, and methods of treating diseases, disorders or symptoms thereof mediated by such metalloenzymes.

  本发明描述了具有金属酶调节活性的化合物，以及治疗由这些金属酶介导的疾病、疾病或症状的方法。